Sign In
Buy ANVS
$1.77
+0.0200 (+1.14%)
At Close: Jun 22, 2026
Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and Hosted by M-Vest on May 26th, 2021
04:30pm, Thursday, 20'th May 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 20, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and
Annovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's Patients
04:30pm, Wednesday, 19'th May 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 19, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and
Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy
06:45am, Thursday, 06'th May 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 6, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) an
Annovis: Novel Approach To Dementia
06:26pm, Saturday, 03'rd Apr 2021
Annovis is a nano cap that went up recently after announcing positive interim data from its phase 2a trial. They will announce complete data by July.
Annovis Bio Presents Novel Treatment For Alzheimer's And Parkinson's Diseases
11:21am, Thursday, 18'th Mar 2021
Annovis Bio, Inc. was one of the sponsors for the Benzinga Global Small-Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment
Annovis Bio Stock Is Trading Higher After Parkinson's Med Shows Improvement In Speed, Coordination
09:24am, Tuesday, 16'th Mar 2021
Annovis Bio Inc (NYSE: ANVS) reported positive interim data from Phase 2a trial evaluating ANVS401, its lead drug candidate for Alzheimer's disease (AD) and Parkinson's disease (PD). In one test t
Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit
07:05am, Thursday, 11'th Mar 2021
BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual
Annovis Bio to Present at the BIO CEO & Investor Digital Conference
06:45am, Tuesday, 16'th Feb 2021
BERWYN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other n
Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
06:45am, Tuesday, 02'nd Feb 2021
Berwyn, Pennsylvania--(Newsfile Corp. - February 2, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD)
Annovis Bio: A Speculative Buy For Their Novel Alzheimer's Disease Treatment
10:16am, Wednesday, 06'th Jan 2021
ANVS, a clinical-stage biotech, develops novel treatments addressing Alzheimer's Disease (AD), Parkinson's Disease (PD) and other neurodegenerative diseases. ANVS believes that their lead candidate, A
Annovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference
06:45am, Tuesday, 05'th Jan 2021
Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2021) - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and oth
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
06:45am, Thursday, 17'th Dec 2020
BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other ne
Annovis Bio Showcases its Unique Approach to Alzheimer's at the New York Academy of Sciences
06:45am, Tuesday, 15'th Dec 2020
BERWYN, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other ne
BERWYN, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other ne
Here is What Hedge Funds Think About Annovis Bio, Inc. (ANVS)
07:55pm, Thursday, 26'th Nov 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 817 13F
